Table 1.
Baseline data of 30 active rheumatoid arthritis patients naïve to biologics
|
Group
|
All (n = 30)
|
High-IR (n = 18)
|
Low-IR (n = 12)
|
P
value1
|
| Sex (female %) | 83.3 | 77.8 | 91.7 | 0.622 |
| Age (yr) | 50.3 ± 11.4 (30-74) | 49.2 ± 10.5 (30-65) | 51.8 ± 12.9 (31-74) | 0.445 |
| BMI (kg/m2) | 22.32 ± 1.93 (19.3-26.3) | 22.56 ± 2.15 (19.7-26.3) | 21.97 ± 1.57 (19.3-24.8) | 0.624 |
| Seropositivity (%) | 86.7 | 83.3 | 91.7 | 0.632 |
| DAS28 | 6.291 ± 0.530 (5.16-7.37) | 6.499 ± 0.472 (5.56-7.37) | 5.980 ± 0.470 (5.16-6.69) | 0.008 |
| ESR (mm/h) | 51.7 ± 17.2 (26-88) | 54.4 ± 18.5 (28-88) | 47.6 ± 14.8 (28-70) | 0.279 |
| CRP (mg/L) | 21.20 ± 6.90 (10.4-36.5) | 22.27 ± 7.31 (10.4-36.5) | 19.71 ± 6.21 (10.7-29.5) | 0.341 |
| Glucose (mg/dL) | 88.7 ± 8.5 (66-104) | 90.8 ± 9.3 (66-104) | 85.6 ± 6.1 (77-98) | 0.035 |
| Insulin (μU/mL) | 11.870 ± 5.029 (4.64-24.84) | 14.710 ± 4.527 (9.07-24.84) | 7.605 ± 1.410 (4.64-9.14) | < 0.001 |
| HOMA-IR | 2.639 ± 1.185 (1.07-5.89) | 3.331 ± 1.036 (2.04-5.89) | 1.602 ± 0.294 (1.07-2.00) | < 0.001 |
| QUICKI | 0.3353 ± 0.0222 (0.296-0.380) | 0.3207 ± 0.0135 (0.296-0.343) | 0.3573 ± 0.0117 (0.344-0.380) | < 0.001 |
| Methotrexate (%) | 100 | 100 | 100 | 1.0 |
| Dosage (mg/wk) | 15 | 15 | 15 | 1.0 |
| Prednisolone (%) | 26.7 | 22.2 | 33.3 | 0.678 |
| Daily dosage2 (mg/d) | 5.6 ± 1.8 | 6.3 ± 2.5 | 5.0 ± 0.0 | 1.0 |
| Total dosage3 (mg) | 865.6 ± 258.4 | 887.5 ± 386.5 | 843.8 ± 71.8 | 0.914 |
| Hydroxychloroquine (%) | 100 | 100 | 100 | 1.0 |
| Sulfasalazine (%) | 20.0 | 16.7 | 25.0 | 0.660 |
| Leflunomide (%) | 10.0 | 11.1 | 8.3 | 1.0 |
1
High-IR vs Low-IR.
2
Average daily prednisolone dosage in 1-mo period before enrolment into this study.
3
Total exposure of prednisone dosages in 6-mo period before enrolment into this study.
HOMA-IR: Homeostatic model assessment-insulin resistance; QUICKI: Quantitative Insulin Sensitivity Check Index; BMI: Body mass index; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28: Disease Activity Score 28.